Clinical Trials Logo

Filter by:
NCT ID: NCT00120900 Completed - Clinical trials for Osteoarthritis, Knee

Evaluation of GW406381 in Treating Adults With Osteoarthritis Of The Knee

Start date: May 2005
Phase: Phase 3
Study type: Interventional

This study was designed to evaluate the effectiveness of GW406381 (a COX-2 inhibitor) in treating the signs and symptoms of osteoarthritis of the knee.

NCT ID: NCT00119626 Completed - Cerebral Stroke Clinical Trials

Safety and Effectiveness of NXY-059 for the Treatment of Patients Who Have Suffered From a Stroke

Start date: June 2003
Phase: Phase 3
Study type: Interventional

This study will determine if NXY-059 will reduce functional disability from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strength and coordination.

NCT ID: NCT00119457 Completed - Clinical trials for Venous Thromboembolism

Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)

Start date: January 2005
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether TTP889 prevents venous thromboembolism following surgery to repair hip fracture.

NCT ID: NCT00117598 Completed - Lymphoma Clinical Trials

Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)

OPTIMAL
Start date: May 2005
Phase: Phase 3
Study type: Interventional

This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).

NCT ID: NCT00116935 Completed - Sarcoma Clinical Trials

Study Comparing 12 Months Versus 36 Months of Imatinib in the Treatment of Gastrointestinal Stromal Tumor (GIST)

Start date: February 2004
Phase: Phase 3
Study type: Interventional

In this study, patients who have been diagnosed with gastrointestinal stromal tumor (GIST) will be randomly allocated in a 1:1 ratio to receive imatinib (Gleevec) either for 12 or for 36 months following surgery. The study participants are required to have a histologically verified GIST with a high risk of GIST recurrence despite complete removal of all macroscopic GIST tissue at surgery. The high/very high risk of recurrence is defined as one of the following: 1) the largest tumor diameter is over 10 cm; 2) the mitosis count is high (over 10 mitoses per 50 high power microscope fields, HPFs); 3) the largest tumor diameter over 5 cm and the mitosis count is over 5/50 HPFs; 4) tumor spillage has taken place into the abdominal cavity at the time of surgery or following spontaneous tumor rupture. All study participants will receive imatinib 400 mg/day orally, but the duration of imatinib administration will be determined randomly (either for 12 or for 36 months). The study participants will be followed up using blood tests and computed tomography (or MRI) of the abdomen. The computed tomography examinations will be performed at 6 month intervals for a median of 5 years. A total of 280 patients will be entered into the study. The study hypothesis is that adjuvant imatinib may prevent some of the GIST recurrences, and that there may be a difference in the rate of GIST recurrence between the two groups.

NCT ID: NCT00116831 Completed - Atherosclerosis Clinical Trials

Rosiglitazone Versus a Sulfonylurea On Progression Of Atherosclerosis In Patients With Heart Disease And Type 2 Diabetes

Start date: January 2005
Phase: Phase 3
Study type: Interventional

The purpose of this study is to test the safety and effectiveness of rosiglitazone against a sulfonylurea in reducing or slowing the development of atherosclerosis in the blood vessels of the heart.

NCT ID: NCT00115791 Completed - Atrial Fibrillation Clinical Trials

Study to Determine the Response and Effectiveness of RSD1235 in Subjects With Atrial Fibrillation or Atrial Flutter

Start date: June 2004
Phase: Phase 3
Study type: Interventional

The purpose of this study is to demonstrate the effectiveness of RSD1235 compared with placebo, in the conversion of atrial fibrillation or atrial flutter to sinus rhythm.

NCT ID: NCT00114777 Completed - Clinical trials for Renal Transplantation

Study of Belatacept in Subjects Who Are Undergoing a Renal Transplant

BENEFIT-EXT
Start date: February 2005
Phase: Phase 3
Study type: Interventional

The purpose of this trial is to learn if Belatacept is effective and safe as a first line of immunosuppression treatment in patients undergoing a renal transplant where the donor kidney is obtained in patients with extended criteria.

NCT ID: NCT00113607 Completed - Ovarian Cancer Clinical Trials

An Efficacy and Safety Study for Yondelis (Trabectedin) in Patients With Advanced Relapsed Ovarian Cancer

Start date: April 2005
Phase: Phase 3
Study type: Interventional

The purpose of the study is to compare the progression-free survival (PFS) of the combination of trabectedin + DOXIL with DOXIL monotherapy in patients with ovarian cancer.

NCT ID: NCT00111800 Completed - Clinical trials for Diabetes Mellitus, Type 2

A New Oral Treatment For Type II Diabetes Mellitus

Start date: April 28, 2005
Phase: Phase 2
Study type: Interventional

This is a 24-week study investigating the safety and efficacy of several dosages of a potential new oral medicine for Type II diabetes mellitus.